MX2021014195A - Complejos de naftoquinona de carbeno de oro funcionalizados para su uso en el tratamiento del cancer. - Google Patents
Complejos de naftoquinona de carbeno de oro funcionalizados para su uso en el tratamiento del cancer.Info
- Publication number
- MX2021014195A MX2021014195A MX2021014195A MX2021014195A MX2021014195A MX 2021014195 A MX2021014195 A MX 2021014195A MX 2021014195 A MX2021014195 A MX 2021014195A MX 2021014195 A MX2021014195 A MX 2021014195A MX 2021014195 A MX2021014195 A MX 2021014195A
- Authority
- MX
- Mexico
- Prior art keywords
- naphthoquinone
- cancer
- complexes
- treatment
- functionalized gold
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/12—Gold compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/10—Silver compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962851187P | 2019-05-22 | 2019-05-22 | |
| PCT/US2020/034415 WO2020237225A1 (en) | 2019-05-22 | 2020-05-22 | Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014195A true MX2021014195A (es) | 2022-02-21 |
Family
ID=73459479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014195A MX2021014195A (es) | 2019-05-22 | 2020-05-22 | Complejos de naftoquinona de carbeno de oro funcionalizados para su uso en el tratamiento del cancer. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12577262B2 (enExample) |
| EP (1) | EP3972981A4 (enExample) |
| JP (1) | JP2022532801A (enExample) |
| KR (1) | KR20220024123A (enExample) |
| CN (1) | CN114174305A (enExample) |
| AU (1) | AU2020279478A1 (enExample) |
| CA (1) | CA3140716A1 (enExample) |
| IL (1) | IL288176A (enExample) |
| MX (1) | MX2021014195A (enExample) |
| SG (1) | SG11202112856QA (enExample) |
| WO (1) | WO2020237225A1 (enExample) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201003483D0 (en) | 2010-03-02 | 2010-04-14 | Univ St Andrews | Gold complexes |
| US8900654B2 (en) | 2011-07-29 | 2014-12-02 | Thin Film Electronics, Inc. | Methods of polymerizing silanes and cyclosilanes using N-heterocyclic carbenes, metal complexes having N-heterocyclic carbene ligands, and lanthanide compounds |
| PL2814829T3 (pl) | 2012-02-13 | 2017-06-30 | Bristol-Myers Squibb Company | Związki enediyny, ich koniugaty oraz zastosowanie i sposoby ich wytwarzania |
| WO2017083595A1 (en) | 2015-11-10 | 2017-05-18 | Massachusetts Institute Of Technology | Complexes comprising a platinum compound and an immune checkpoint inhibitor and related methods |
| WO2019006327A1 (en) * | 2017-06-30 | 2019-01-03 | Board Of Regents, The University Of Texas System | OR-CARBENE COMPLEXES CONTAINING NAPHTOQUINONE AND METHODS OF USE |
-
2020
- 2020-05-22 WO PCT/US2020/034415 patent/WO2020237225A1/en not_active Ceased
- 2020-05-22 JP JP2021569297A patent/JP2022532801A/ja active Pending
- 2020-05-22 US US17/595,670 patent/US12577262B2/en active Active
- 2020-05-22 SG SG11202112856QA patent/SG11202112856QA/en unknown
- 2020-05-22 AU AU2020279478A patent/AU2020279478A1/en not_active Abandoned
- 2020-05-22 CA CA3140716A patent/CA3140716A1/en active Pending
- 2020-05-22 MX MX2021014195A patent/MX2021014195A/es unknown
- 2020-05-22 KR KR1020217041752A patent/KR20220024123A/ko not_active Ceased
- 2020-05-22 CN CN202080050300.4A patent/CN114174305A/zh active Pending
- 2020-05-22 EP EP20809519.0A patent/EP3972981A4/en not_active Withdrawn
-
2021
- 2021-11-16 IL IL288176A patent/IL288176A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202112856QA (en) | 2021-12-30 |
| CA3140716A1 (en) | 2020-11-26 |
| US12577262B2 (en) | 2026-03-17 |
| CN114174305A (zh) | 2022-03-11 |
| EP3972981A4 (en) | 2023-05-24 |
| EP3972981A1 (en) | 2022-03-30 |
| KR20220024123A (ko) | 2022-03-03 |
| IL288176A (en) | 2022-01-01 |
| JP2022532801A (ja) | 2022-07-19 |
| US20220340601A1 (en) | 2022-10-27 |
| AU2020279478A1 (en) | 2021-12-09 |
| WO2020237225A1 (en) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20020410A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| ES3063344T3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
| MX2021011209A (es) | Novedosos inhibidores de molécula pequeña de factores de transcripción tead. | |
| PE20191303A1 (es) | Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2 | |
| PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| MX2016001236A (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
| AR100431A1 (es) | Compuestos de pladienolida piridina y métodos de uso | |
| MX380370B (es) | Modulador del receptor de androgeno y usos de este. | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| CL2016002033A1 (es) | Compuestos derivados de benzimidazol-2 amino con actividad inhibidora (midh1 r132h); composición farmacéutica, procedimiento de preparación; uso en el tratamiento de tumores gastrointestinales, tumor endocrino, síndrome mielodisplásico, leucemia, tumor de mamas, , metástasis, entre otros. | |
| MX379297B (es) | Compuestos alqueno tetrasustituidos y su uso. | |
| CY1122441T1 (el) | Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους | |
| UY36075A (es) | Derivados de tubulisina | |
| AR105592A1 (es) | b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS | |
| EA201890894A1 (ru) | Комбинированная терапия | |
| MX2017012102A (es) | Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti. | |
| CY1122968T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο | |
| CY1124529T1 (el) | Ενωσεις λευκοχρυσου λειτουργικοποιημενες με μονομηλεινιμιδιο για θεραπεια καρκινου | |
| CO2020001107A2 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa | |
| PH12016502132B1 (en) | Aryl-or heteroaryl-substituted benzene compounds | |
| DOP2018000238A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| CL2020002604A1 (es) | Ciertos compuestos de pladienolida y métodos de uso. | |
| MX2018014576A (es) | Nanopartículas para el suministro de fármaco y tratamientos para el cáncer resistente a fármacos. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. |